NCT05433987

Immune Activation Markers in HIV-infected Patients Switching to Long Acting Dual Therapy

Study Aiming to Measure the Impact on Immune Activation and Inflammatory Markers of Switching From a Triple Combination Antiretroviral Therapy (cART) to a Long Acting Dual Therapy in HIV-infected Patients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 20 (actual)
• Sponsor: Centre Hospitalier de Cannes Simone Veil · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to measure the impact on immune activation and inflammatory markers of switching from a triple combination antiretroviral therapy (cART) to a long acting dual therapy in HIV-infected patients

Detailed description

Patients meeting the inclusion criteria will be offered to participate to the study. In case of acceptance by given their writting consent, 6 ml of blood will be collected for measuring immune activation and inflammatory markers, during the blood test scheduled for the routine follow-up. Six months after cART change, an equal volume of blood will be collected for measuring the same immune activation and inflammatory markers

Conditions

• HIV-1-infection

Timeline

• Start date: 2022-07-28
• Primary completion: 2023-11-17
• Completion: 2023-11-17
• First posted: 2022-06-27
• Last updated: 2024-08-28

Locations

1 site across 1 country: France